- UCB’s core EPS for the first half of 2024 was EU2.10, compared to EU2.63 year-over-year, beating estimates of EU1.95.
- Revenue came in at EU2.79 billion, surpassing estimates of EU2.75 billion.
- Drug Sales:
- Vimpat: EU172 million, higher than the estimate of EU165.6 million.
- Keppra: EU309 million, exceeding the estimate of EU296.3 million.
- Briviact: EU327 million, above the estimate of EU318 million.
- Adjusted EBITDA was EU652 million, which is a 19% decrease year-over-year but still beat the estimate of EU637.4 million.
- Net income was EU208 million, down 33% year-over-year, but higher than the estimated EU174.4 million.
- Net debt stood at EU2.61 billion.
- Year Forecast:
- Revenue is expected to be at the high end of EU5.5 billion to EU5.7 billion, in line with the estimate of EU5.69 billion.
- Adjusted EBITDA margin is expected to remain between 23% and 24.5%, close to the estimate of 24.7%.
- Core EPS is projected to be between EU3.70 and EU4.40, compared to the estimate of EU4.26.
- Analyst Ratings:
- 13 Buy ratings
- 7 Hold ratings
- 2 Sell ratings
A look at UCB SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have assessed the long-term outlook for UCB SA, a biopharmaceutical company known for its focus on treating central nervous system disorders and inflammatory diseases. The company has been given varying scores across different factors: Value, Dividend, and Growth all received a moderate score of 2. On the positive side, UCB SA scored high in Resilience with a score of 4, indicating the company’s ability to weather challenging market conditions. Momentum, which scored the highest at 5, suggests a strong upward trend in the company’s performance.
Overall, despite moderate scores in Value, Dividend, and Growth, UCB SA stands out for its high Resilience and Momentum scores. This suggests that the company may have a solid foundation to navigate market uncertainties and is experiencing positive trends in its performance and growth. Investors interested in UCB SA may find these scores indicative of a company with strong potential for long-term success in the biopharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
